Comparative Pharmacology
Head-to-head clinical analysis: ACANYA versus BENZACLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACANYA versus BENZACLIN.
ACANYA vs BENZACLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acanya is a combination of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, an oxidizing agent with bactericidal and keratolytic activity. Benzoyl peroxide exerts its effect by releasing free radical oxygen that oxidizes bacterial proteins and has been shown to reduce Propionibacterium acnes.
BENZACLIN (clindamycin 1% and benzoyl peroxide 5%) is a combination antibacterial agent. Clindamycin is a lincosamide antibiotic that binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis and reducing Propionibacterium acnes growth. Benzoyl peroxide has bactericidal and keratolytic properties; it releases free radical oxygen species that oxidize bacterial proteins, decreasing P. acnes, and also causes drying and peeling of the skin.
Apply a pea-sized amount to the entire face once daily in the evening, topical.
Topical gel applied once or twice daily to affected areas. Each gram contains 1% clindamycin and 5% benzoyl peroxide.
None Documented
None Documented
Clindamycin: after topical application, terminal half-life is approximately 2-3 hours in serum, but clinical relevance is minimal due to low systemic levels. Benzoyl peroxide metabolites have a half-life of ~1-2 hours. The clinical effect is primarily local with sustained antimicrobial and keratolytic activity.
After topical application, plasma concentrations of clindamycin are negligible; the systemic half-life of clindamycin from absorbed fraction is approximately 2.5-3 hours in adults. However, due to minimal systemic absorption, the terminal half-life is not clinically relevant for topical therapy.
Acanya (clindamycin phosphate 1.2% and benzoyl peroxide 2.5% gel) is a fixed-dose combination applied topically. Systemic absorption is minimal. Clindamycin: <0.1% of applied dose excreted renally as parent and metabolites. Benzoyl peroxide: metabolized to benzoic acid, which is conjugated and excreted renally; <5% of applied dose appears in urine. Fecal excretion is negligible.
Benzaclin (clindamycin 1% - benzoyl peroxide 5%) is a topical formulation; systemic absorption is minimal. After topical application, less than 1% of clindamycin is absorbed. Absorbed clindamycin is primarily excreted in urine (10% as active drug, 90% as metabolites) and feces (<5%). Benzoyl peroxide is metabolized to benzoic acid, which is conjugated and excreted in urine. Overall, renal excretion accounts for the majority of clearance of absorbed components.
Category C
Category C
Topical Antibiotic
Topical Antibiotic